U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                   FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended March 31, 2002

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from                to
                                    --------------    ---------------


                          Commission File No. 333-51414
                          -----------------------------


                           RUBICON MEDICAL CORPORATION
                           ---------------------------
              (Name of Small Business Issuer in its Charter)


           Delaware                                        87-0361403
           --------                                        ----------
   (State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
    incorporation or organization)

                               2064 West Alexander
                           Salt Lake City, Utah 84119
                           ---------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (801) 886-9000
                ------------------------------------------

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the Registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

(1)  Yes  X     No                 (2)  Yes  X     No
         ---     ---                        ---      ---

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                                 Not applicable.


                      APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date:

                                   52,026,334

                                 March 31, 2002

<PAGE>

                         PART I - FINANCIAL INFORMATION


Item 1.   Financial Statements.
-------------------------------

                   FORWARD LOOKING INFORMATION AND RISK FACTORS

     Rubicon Medical Corporation (the "Company") or its representatives may make
forward looking statements, oral or written, including statements in the
Report's Management's Discussion and Analysis of Financial Condition and Results
of Operation, press releases and filings with the Securities and Exchange
Commission, regarding estimated future net revenues from operations, planned
capital expenditures (including the amount and nature thereof), the Company's
projected financial position, results of operations, business strategy and other
plans and objectives for future operations. These statements are forward-looking
statements, within the meaning of Section 27A of the Securities Act of 1993 and
Section 21E of the Securities Exchange Act, which reflect Management's current
views with respect to future events and financial performance.

     Although the Company believes that the expectations reflected in these
forward looking statements are reasonable, there can be no assurance that the
actual results or developments anticipated by the Company will be realized or,
even if substantially realized, that they will have the expected effects on its
business or results of operations. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. Such factors include but are not limited to the
Company's manufacturing process, reaching the milestones of the Abbott
Agreement, engineering difficulties, difficulties in connection with the
Company's business operations and other risks.

     These forward-looking statements are also subject to certain risks and
uncertainties including, but not limited to, future financial performance and
future events, competitive pricing for services, costs of obtaining capital as
well as national, regional and local economic conditions. Actual results could
differ materially from those addressed in the forward-looking statements. Due to
such uncertainties and risks, readers are cautioned not to place undue reliance
on such forward-looking statements, which speak only as of the date thereof.

     All subsequent oral and written forward-looking  statements attributable to
the Company or persons  acting on its behalf are  expressly  qualified  in their
entirety by these  factors.  The Company  assumes no obligation to update any of
these statements.

     The Financial  Statements of the Registrant  required to be filed with this
10-QSB  Quarterly  Report  were  prepared  by  management,  and  commence on the
following page,  together with Related Notes. In the opinion of management,  the
Financial  Statements  fairly present the financial  condition of the Registrant
for the periods then ended.
<PAGE>
<TABLE>
                                                   RUBICON MEDICAL CORPORATION
                              Condensed Consolidated Balance Sheet (Unaudited)
                                                                March 31, 2002
<CAPTION>


          ASSETS
<S>                                                             <C>
Current Assets
  Cash and cash equivalents                                      $  76,000
  Accounts receivable, net                                           7,000
  Income tax receivable                                            134,000
  Prepaid expenses                                                  17,000
  Net assets from discontinued operations                           48,000
                                                               -----------
     Current Assets                                                282,000
                                                               -----------
Property and equipment, net                                        264,000
Intangible assets, net                                              58,000
                                                               -----------
     Total assets                                              $   604,000
                                                               ===========

     LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities
 Accounts payable                                              $    86,000
 Accrued liabilities                                                 1,000
 Current portion of long-term debt                                  41,000
                                                               -----------
     Total Current Liabilities                                     128,000

Long-term debt                                                      51,000
                                                               -----------
     Total liabilities                                             179,000
                                                               -----------

Commitments and contingencies                                            -

STOCKHOLDERS' EQUITY
  Common stock, $.001 par value, 100,000,000 shares
    authorized, 52,026,334 shares issued and outstanding            52,000
  Additional paid in capital                                     3,010,000
  Deferred compensation                                            (99,000)
  Treasury stock, at cost (50,000 shares)                          (65,000)
  Accumulated deficit                                           (2,473,000)
                                                               -----------
     Total stockholders' equity                                    425,000

                                                               -----------
     Total liabilities and stockholders' equity                $   604,000
                                                               ===========
</TABLE>
See notes to condensed consolidated financial statements.
                                2
<PAGE>
<TABLE>
                                                   RUBICON MEDICAL CORPORATION
                    Condensed Consolidated Statement of Operations (Unaudited)
<CAPTION>
                                                   Three Months Ended
                                                       March 31,
                                                    2002          2001
                                                 -----------  -----------
<S>                                               <C>        <C>
Net sales                                         $        -  $   603,000
Cost of sales                                              -       32,000
                                                 -----------  -----------
  Gross profit                                             -      571,000
                                                 -----------  -----------
Operating Expenses:
  Depreciation and amortization                       44,000       45,000
  General and administrative                         324,000      182,000
  Research and development                           131,000      175,000
                                                 -----------  -----------
                                                     499,000     402,000
                                                 -----------  -----------
  Income (loss) from Continuing Operations          (499,000)    169,000
                                                 -----------  -----------
Other income (expense):
  Interest income                                      1,000      22,000
  Interest expense                                    (7,000)    (14,000)
                                                 -----------  ----------
  Other income (expense)                              (6,000)      8,000
                                                 -----------  ----------
  Income (loss) from continuing operations
    before provision for income taxes               (505,000)    177,000
                                                 -----------  ----------
Income tax (expense) benefit:
  Current                                                  -           -
  Deferred                                                 -     (60,000)
                                                 ----------- -----------
                                                           -     (60,000)

  Net income (loss) from continuing operations      (505,000)    117,000

  Loss from discontinued operations                   (8,000)    (79,000)
                                                 ----------- -----------
  Net (loss) income                              $  (513,000)$    38,000
                                                 =========== ===========
Income (loss) per common share-basic and diluted
  Continuing operations                          $     (0.01)$      0.00

  Discontinued operations                              (0.00)      (0.00)
                                                 ----------- -----------
                                                 $     (0.01)$      0.00
                                                 =========== ===========
Weighted average shares-basic and diluted         51,927,000  48,339,000
                                                 =========== ===========
</TABLE>
See notes to condensed consolidated financial statements.
                                3
<PAGE>
<TABLE>
                                                   RUBICON MEDICAL CORPORATION
                    Condensed Consolidated Statement of Cash Flows (Unaudited)
<CAPTION>
                                                   Three Months Ended
                                                       March 31,
                                                     2002          2001
<S>                                                <C>          <C>
Cash flows from operating activities:              ----------- -----------
  Net (loss) income                                $  (513,000)$    38,000
  Loss from discontinued operations                      8,000      79,000
  Adjustments to reconcile net (loss) income to net
    cash used by operating activities:
    Depreciation and amortization                       44,000      45,000
    Stock and stock options issued for services         21,000     119,000
    Deferred income taxes                                    -      60,000
    Loss on disposal of assets                               -           -
    Bad debt expense                                     9,000           -
  (Increase) decrease in:
    Accounts receivable                                160,000     (69,000)
    Prepaid expenses                                     4,000           -
    Income tax receivable                               29,000           -
  Increase (decrease) in:
    Accounts payable                                   (29,000)      3,000
    Accrued liabilities                                 (2,000)          -
    Deferred revenue                                         -    (333,000)
                                                   ----------- -----------
     Net cash used in continuing operations           (269,000)    (58,000)
     Net cash used in discontinued operations          (60,000)    (34,000)
                                                   ----------- -----------
     Net cash used in operating activities            (329,000)    (92,000)
                                                   ----------- -----------
Cash flows from investing activities:
  Increase in intangible assets                        (43,000)          -
  Purchase of property and equipment                    (6,000)    (49,000)
                                                   ----------- -----------
     Net cash used in investing activities             (49,000)    (49,000)
                                                   ----------- -----------
Cash flows from financing activities:
  Principal payments on long-term debt                 (32,000)    (30,000)
  Purchase of treasury stock                           (65,000)          -
  Proceeds from issuance of common stock               195,000           -
                                                   ----------- -----------
     Net cash provided by (used in) continuing
     operations                                         98,000     (30,000)
     Net cash used in discontinued operations          (10,000)   (259,000)
                                                   ----------- -----------
Net cash provided by (used in) financing activities     88,000    (289,000)
                                                   ----------- -----------
Net decrease in cash and cash equivalents             (290,000)   (430,000)


Cash and cash equivalents at beginning of period       366,000   1,421,000
                                                   ----------- -----------
Cash and cash equivalents at end of period         $    76,000 $   991,000
                                                   =========== ===========
</TABLE>
                                4
See notes to condensed consolidated financial statements.
<PAGE>
                                                   RUBICON MEDICAL CORPORATION
                    Condensed Consolidated Statement of Cash Flows (Unaudited)

Supplemental Cash Flow Information (unaudited):

During the three months ended March 31, 2002, the Company:

   * Issued common stock in exchange for debt of $200,000.

   * Issued common stock in satisfaction of a liability of $280,000.

                                                   Three Months Ended
                                                       March 31,
                                                     2002          2001
Cash paid during the period for:
   Interest                                      $   7,000     $  14,000
                                                 =========     =========
   Income Taxes                                  $       -     $       -
                                                 =========     =========


                                5
See notes to condensed consolidated financial statements.
<PAGE>
                                                   RUBICON MEDICAL CORPORATION
                          Notes to Condensed Consolidated Financial Statements

                                                                March 31, 2002

1.  Interim Financial Statements.

The condensed consolidated financial statements for the three months ended March
31, 2002 and 2001, are unaudited. However, the Company, in its opinion, has made
all adjustments (consisting only of normal recurring adjustments) necessary to
present fairly the financial position, results of operations and cash flows for
the periods presented. The financial statements and notes thereto should be read
in conjunction with the financial statements and notes for the years ended
December 31, 2001 and 2000, included in the Company's Form 10KSB filed on March
28, 2002 with the Securities and Exchange Commission. The results of operations
and cash flows for the three months ended March 31, 2002, are not necessarily
indicative of results for the year ending December 31, 2002.

2.  Organization and Nature of Business.

Rubicon Medical Corporation (the Company), commenced operations on December
11, 1996 as Rubicon Medical, L.C. (the L.C.), a Utah limited liability
company.  On May 1, 2000, the Members of the L.C. exchanged their membership
interests' for 100% of the common stock of Rubicon Medical, Inc. (Rubicon), a
Utah corporation.

Effective October 11, 2000, Hi-Tech Venture, Inc. (Hi-Tech), a publicly traded
Delaware corporation with no ongoing operations, acquired 100% of the stock of
Rubicon by issuing 36,000 shares of Hi-Tech common stock for each share of
Rubicon common stock and on share of Hi-Tech mandatory redeemable preferred
stock for each Rubicon mandatory redeemable preferred share. Because the shares
issued in the acquisition represent control of the total shares of Hi- Tech's
common stock immediately following the acquisition, Rubicon is deemed for
financial reporting purposes to have acquired Hi-Tech in a recapitalization of
Rubicon. The surviving entity reflects the assets and liabilities of Rubicon and
Hi-Tech. The issued common stock is that of Hi- Tech and the historical
operations are that of Rubicon and Hi-Tech after October 11, 2000.

Effective November 3, 2000, Hi-Tech changed its name to Rubicon Medical
Corporation.
                                6
<PAGE>
                                                   RUBICON MEDICAL CORPORATION
                          Notes to Condensed Consolidated Financial Statements

3.  Loss Per Share and Pro Forma Loss Per Share.

Basic loss per share excludes dilution and is computed by dividing net losses
available to common stockholders by the weighted average number of common shares
outstanding for the period. Diluted earnings per share reflect the potential
dilution that could occur if options or warrants to issue common stock were
exercised into common stock. Common stock equivalents are not included in the
diluted loss per share calculation when their effect is antidilutive.

4.  Discontinued Operations.

In an effort to maximize growth and attain high-margin revenues, management has
determined to focus solely on the technology development segment and has
discontinued the contract manufacturing and equipment manufacturing segments of
its operations. The Company recognized an estimated loss on disposition of
discontinued operations of $582,000 for the year ended December 31, 2001.

Net assets and condensed discontinued operations as of March 31, 2002 are as
follows:

    Assets:
       Inventory                           $   11,000
       Property and equipment, net            157,000
       Receivables                             15,000
                                           ----------
                                           $  183,000
                                           ==========
    Liabilities:
       Note payable                        $ (135,000)
                                           ----------
    Net assets of discontinued operations  $   48,000
                                           ==========
                                7
<PAGE>
                                                   RUBICON MEDICAL CORPORATION
                          Notes to Condensed Consolidated Financial Statements

4.  Discontinued Operations-continued

                                                 Three Months Ended
                                                    March 31,
                                                   2002        2001

                  Revenue                     $  76,000     $  117,000
                  Costs and Expenses             84,000        236,000
                                              ---------     ----------
                  Net loss before income taxes   (8,000)      (119,000)
                  Income Taxes                        -         40,000
                                              ---------     ----------
                                              $  (8,000)    $  (79,000)
                                              ==========    ===========
                                8
<PAGE>

Item 2.   Management's Discussion and Analysis.
-----------------------------------------------

General.
--------

      The general characteristics of Rubicon Medical Corporation have not
changed since we filed our form 10-KSB Annual Report for the year ended December
31, 2001 and our post-effective amendment to our Registration Statement filed on
April 22, 2002. Rubicon Medical Corporation continues to conduct research and
development activities to generate medical technologies that will be
manufactured and marketed worldwide. The primary focus of our research and
development activities is the Rubicon Filter. The Rubicon Filter is an embolic
protection device for use in interventional vascular procedures to reduce
embolic complications during stenting. The Rubicon Filter platform will be
utilized to launch additional products for use in various other areas of the
vasculature system.

     Rubicon has focused on investing in the future during the first quarter of
2002. We have successfully re-organized our operations and have discontinued the
contract manufacturing and equipment manufacturing business units. In addition,
we have disposed of the equipment manufacturing unit by transitioning out of the
Accurate Designs acquisition, and in the process eliminated a substantial amount
of short-term and long-term debt obligations associated with that acquisition.

     Furthermore,  we have  recognized  all of the  deferred  revenue  from  the
licensing  agreement  with  Abbott  Laboratories  and have  engaged  in  raising
additional  working  capital  to fund our  operations.  Our  Board of  Directors
authorized us to offer up to 3,000,000  shares of our common stock at a price of
$0.50 per  share.  As of May 1,  2002,  we have sold  1,871,000  shares and have
raised $935,500. Until we receive additional revenues from the license agreement
regulatory  milestones,  we  will  continue  to  raise  additional  capital.  We
anticipate  that some of the  license  fee  payments  will be  received in 2002.
However, it is difficult to foresee how the Food and Drug  Administration  (FDA)
will respond to Abbott Laboratories regulatory  submissions.  Further, we cannot
guarantee  that  regulatory  approvals  will be granted  in the  United  States,
Europe, or other countries.

     We do not believe that the events of September 11, 2001, will have any
material effect on our business operations.

Three Months Ending March 30, 2002 Compared with 2001.
-------------------------------------------------------

     Results of Continued Operations.
     ----------------------------------

     Continuing operations had a net loss of $505,000 for the first quarter (Q1)
2002, compared to a net profit of $117,000 for the same period in 2001. All of
the remaining deferred revenue that resulted from the initial guardian licensing
agreement with Abbott was recognized in fiscal year 2001. In addition, we also
completed our consulting and development obligations related to the guardian
project in 2001,and did not have any revenue related to its further development.
As a result, continuing operations did not generate revenues for Q1 2002,
compared to $603,000 for the same period in Q1 2001. Due to the nature of
research and development in the medical device industry, the timing of revenues
generated through the Guardian system is unpredictable and is dependant on the
terms of our existing licensing agreement. Therefore, we expect any future
revenues to come through large lump sum payments. We anticipate our operations
will generate revenues during the fiscal year 2002. However, we cannot predict
when such revenues will occur, nor can we guarantee that any future payments
will be received.
<PAGE>
          Rubicon is currently working on a number of new technologies. However,
we did not file any new patent applications during the first quarter 2002.
Rubicon's research and development engineers are currently working on
improvements to our existing technologies; therefore, we anticipate we will be
able to file additional patents in 2002.

     General and administrative expenses for Q1 2002 were $324,000 compared to
$182,000 for the same period in 2001. The increase is primarily due to the
following factors. First, during the first quarter 2001 we were able to allocate
$32,000 in operating expenses to cost of goods sold, compared to an allocation
of $0 for the same period in 2002. Second, salaries for officers increased due
to the hiring of Harold "Butch" Wolcott as Chief Operating Officer, doubling the
expense for this account. Salaries for officers for Q1 2002 were $46,000
compared to $23,000 for the same period in 2001. Finally, both our legal and
investor relations expenses increased as a result of becoming a public company.
Our legal expenses increased by approximately $17,000 and our investor relations
increased by $10,000 for the first quarter 2002, compared to the same period in
2001.

     Results of Discontinued Operations.
     -----------------------------------

     Lower than expected revenues, and the continued losses associated with both
the equipment  and contract  manufacturing  business  segments,  contributed  to
Rubicon's  decision to eliminate these business  segments.  On January  14,2002,
Rubicon's  Board of  Directors  unanimously  determined  to focus  solely on the
technology development and licensing business unit and voted to discontinue both
the contract and equipment manufacturing segments of our business.  Further, the
Board of Directors  decided to expand the technology  development  and licensing
business  unit  to  include  the  development,  manufacture,  and  marketing  of
Rubicon's  proprietary  technologies.  During  the  first  quarter  of 2002,  we
fulfilled  all of the  obligations  that  existed  from our  remaining  contract
manufacturing  customer  work orders.  Therefore,  discontinued  operations  had
revenues  of $76,000 for Q1 2002,  compared  to $117,000  for the same period in
2001.

     Now that our previous contract manufacturing obligations have been met, we
will direct our efforts to the disposition of those assets that will no longer
be required by our continuing operations. We intend to sell at least one of our
existing extrusion lines and all of the related equipment required to operate
it. We hope to have this transaction completed by the end of 2002. However, the
market for this type of equipment is limited; therefore, it will be difficult to
estimate the timing for the sale of the equipment.

Liquidity and Capital Resources.
--------------------------------

     Current obligations at March 31, 2002 have been significantly reduced since
March 31, 2001. Our current liabilities decreased from $1,411,000 at March 31,
2001, to $128,000 at March 31, 2002. However, current assets also decreased from
$2,286,000 at March 31, 2001 to $282,000 at March 31, 2002. As a result, working
capital decreased from $875,000 at March 31,2001 to $154,000 at March 31, 2002.
The decrease can be attributed primarily to the following items.

     First, our research and development timetable and the development of the
Rubicon Filter required us to expend substantial resources over the last twelve
months. In addition, in the first quarter 2002, the Company's operations did not
generate revenues as we were transitioning out of contract and equipment
manufacturing and focusing on research and development activities that will
generate medical technologies that we hope to manufacture and market worldwide.
Therefore, existing cash, as well as cash raised through the private placement
of our securities (discussed below), has been used to fund operations over the
last year. During the first quarter 2002, operating activities for the first
quarter 2002, used $329,000 cash compared to $92,000 used in the first quarter
2001.
<PAGE>

     Second, $100,000 was used to make a payment to the former owner of Accurate
Designs and  repurchase  50,000  shares of  Rubicon's  common  stock held by the
former owner as part of the Accurate Designs  "Accurate"  settlement  agreement.
The fair market value of the shares purchased was $65,000.

     The  decrease  in cash was  partially  offset  by two  events.  First,  the
deferred  revenue  balance of $1,000,000 that existed at March 31 2001, from the
Abbott  Laboratories  license  agreement,  was completely  recognized during the
fiscal year 2001. Therefore,  we do not have a deferred revenue balance at March
31, 2002.  Second, the agreement to transfer the assets acquired in the Accurate
acquisition, also satisfied all of the remaining obligations that existed out of
the original asset purchase  transaction.  The original purchase  agreement with
Accurate was structured as an installment purchase,  with a total purchase price
of $2,000,000.  One million dollars was to be paid in cash and $1,000,000 was to
be paid in shares of  Rubicon's  common  stock.  A balance  of  $500,000  of the
$1,000,000  existed at March 31, 2001.  In addition,  shares of our common stock
were to be  delivered  one  year  from  the date a  public  trading  market  was
established  for these  shares.  Our common  stock was listed for trading on the
Electronic  Bulletin Board in November 2001;  which gave us until November 2002,
to deliver one million  dollars worth of Rubicon  common  stock.  Because of the
February  2002  settlement  agreement,  we  were  able  to  eliminate  from  our
continuing  operations  all of our current  obligations  related to the Accurate
Designs acquisition.

     Rubicon has been successful in raising additional capital through the
private placement of our securities. In October 2001, our Board of Directors
authorized a private placement of up to 3,000,000 shares of our common stock at
a price of $0.50 per share. As of May 1, 2002, Rubicon has raised $935,500 in
the private placement in exchange for the issuance of 1,871,000 shares of common
stock. We do not anticipate we will need to sell the remaining 1,129,000
authorized shares related to this private placement. However, if our technology
development and licensing operations do not generate second quarter revenues, we
intend to sell additional shares of common stock.

     Revenue generated from the license of the Guardian system to Abbott
Laboratories has helped support all of our operations for the past year and a
half. Now that our focus has shifted entirely to developing, manufacturing, and
marketing our own proprietary technologies, we expect capital expenditures for
technology development to be higher than they have been in the past. However,
future capital expenditures will depend on the manufacturing requirements
related to our existing technologies and our ability to market these
technologies effectively, as well as our ability to raise additional capital.

                           PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
----------------------------

     In January, 2002, we filed an Arbitration Demand with the American
Arbitration Association, seeking the rescission of our acquisition of Accurate
Designs or, in the alternative, damages in an amount to be determined at a
hearing on the matter. We also sought attorney's fees incurred in the action.
<PAGE>

     Effective February 1, 2002, we entered into a Mutual Release and Settlement
Agreement with Accurate Designs and Harold Pearsall.

     Under the terms of the Settlement Agreement, we agreed to withdraw the
Arbitration Demand. In addition, the parties agreed as follows:

          Mr. Pearsall agreed to sell to us all of his 50,000
          outstanding shares of Rubicon common stock, in exchange for
          $100,000 cash, payable upon execution of the Settlement Agreement;

          Rubicon agreed to return all Accurate Designs assets in its possession
          and released to Mr. Pearsall all of its right, title and interest in
          the Accurate Designs assets;

          Rubicon agreed to pay Mr. Pearsall's Cobra premium for up to 18
          months, as long as he remains qualified for Cobra coverage;

          Rubicon agreed not to compete with Mr. Pearsall or Accurate Designs in
          the business of catheter tipping equipment for two years from the date
          of the Settlement Agreement and to forward to Mr. Pearsall all
          inquiries regarding the catheter tipping business;

          Rubicon waived any claim to the installment payments already made
          under the Asset Purchase Agreement and Mr. Pearsall and Accurate
          Designs waived any right to further payments of cash and stock under
          the Asset Purchase Agreement; and

          Mr. Pearsall agreed to pay to Rubicon $15,000 per machine on the
          four catheter tipping machines as a full reimbursement of costs
          associated with the machines.

     The Arbitration Demand and the Mutual Release and Settlement Agreement were
disclosed in a Current Report on Form 8-K that we filed with the Securities and
Exchange Commission on February 14, 2002. See the Exhibit Index, Item 6 of this
Report.

Item 2.   Changes in Securities and Use of Proceeds.
---------------------------------------------------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
------------------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
--------------------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
----------------------------

          None; not applicable.
<PAGE>

Item 6.   Exhibits and Reports on Form 8-K.
-------------------------------------------

          (a)  Exhibits.

               10-KSB Annual Report for the year ended December 31, 2001.*

          (b)  Reports on Form 8-K.

               Current Report on Form 8-K dated February 1, 2002, filed February
               14, 2002.*

               *  Incorporated by reference.

                                   SIGNATURES

          Pursuant to the  requirements of the Securities  Exchange Act of 1934,
     the  Registrant  has duly  caused this Report to be signed on its behalf by
     the undersigned thereunto duly authorized.

                                    RUBICON MEDICAL CORPORATION


Date:  05/15/2002                    By: /s/ Richard J. Linder
     --------------                 -------------------------------------
                                    Richard J. Linder
                                    Chief Executive Officer, President and
                                    Director


Date: 05/15/2002                   By: /s/ Dennis M. Nasella
     --------------                 -------------------------------------
                                    Dennis M. Nasella
                                    Chief Financial Officer and Director


Date:  05/15/2002                  By: /s/ Harold R. Wolcott
     --------------                 -------------------------------------
                                    Harold R. "Butch" Wolcott
                                    Director